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Hospital do Rim from Universidade Federal de São Paulo (dialy-
sis center) where 208 patients make use of human recombinant
erythropoietin (ESA) for anemia management. Structured inter-
views with personnel were arranged to identify workﬂow for
anemia management. Time spent in each activity was registered
using a stop watch by a trained professional. Time spent in less
frequent activities or in activities were the direct relation with
anemia management could not be done were not taken into
consideration for this study. For valuing time and supplies the
dialysis center’s costs data was considered. RESULTS: Total time
spent for ESA administration by the dialysis center for the treat-
ment of 208 patients was 75 days or R$19,758. Assuming the
usage of C.E.R.A. in 100% patients of the center, the time spent
by the staff would be 10 days or R$2683, representing an 86%
reduction versus current practice. Costs of supplies needed for
the administration were R$28,863 for those patients receiving
conventional ESA and R$774 if patients would have received
C.E.R.A. As a result, potential total savings generated with the
use of C.E.R.A. was R$ 45,165 per year in this dialysis center or
R$ 217/patient/year. CONCLUSION: The study suggests that
the adoption of once-monthly C.E.R.A. can bring substantial
savings for the dialysis center: R$44,847 per year or R$216 per
patient per year. Once-monthly C.E.R.A. could also improve
resource utilization and enable health care staff to focus more
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OBJECTIVE: To compare the health-related quality of life
(HRQOL) between patients undergoing continuous ambulatory
peritoneal dialysis (CAPD), automated peritoneal dialysis (APD)
and haemodialysis (HD) in the “IMSS” (Mexican Institute of
Social Security) in Guadalajara. METHODS: Transverse analytic
study included 131 patients, in peritoneal dialysis, 18 years,
any gender, or time under dialysis. Patients with acute technique-
related complications, in terminal phase of illness, or with physi-
cal or mental disability were excluded. An interview, clinical
history and detailed physical examination were carried out.
Using the Kidney Disease Quality of Life Short Form (KDQOL-
SFTM), we measured HRQOL.Analysis of variance was used
to examine differences. RESULTS: Patients were studied (50
undergoing CAPD, 34 APD and 47 HD). The average age was
46.2  18.3 years, 53% were females, and 49% were males.
The time in CAPD was 23.4  17.2, APD 23.9  14.2 and
HD 37  34 months. Physical functioning (37  28), pain
(69  25), emotional well-being (52  26), social function
(57  30), and energy/fatigue (37  27) were signiﬁcantly lower
scores in CAPD in comparison with APD (65  31, 93  12,
75  28, 91  15, 60  28) and HD (57  29, 82  17,
69  23, 80  21, 53  28). The Effects of Kidney Disease
(86  15) and Burden of Kidney Disease (58  36) subscales
were lower in APD in comparison with CAPD (76  16 and
24  29, respectively); no differences between CAPD and HD.
The physical component summary was signiﬁcantly higher in
APD (58  22) in comparison with CAPD (46  15) and HD
(34  15). Mental component summary was less in CAPD
(36  15) in comparison with APD (60  22) and HD
(46  15). CONCLUSION: The HRQL in patients undergoing
CAPD was less in comparison with patients with APD and HD.
The physical dimension was higher in patients with APD in
comparison with CAPD and HD, whereas the mental dimension
was less in the CAPD group. There was no signiﬁcant difference
between the APD and HD groups.
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OBJECTIVE: Subjects with overactive bladder (OAB) have
decreased health-related quality of life (HRQL). The positive
effects of fesoterodine (FESO) and tolterodine extended release
(TER) have been established in subjects with OAB using patient-
reported outcomes. This analysis assessed the effects of FESO
and TER on individual items of the King’s Health Questionnaire
(KHQ). METHODS: This is a post hoc analysis of data from a
multicenter, double-blind, placebo (PBO)–controlled trial. Eli-
gible subjects with frequency and urgency or urgency urinary
incontinence were randomized to PBO, FESO 4 mg, FESO 8 mg,
or TER 4 mg for 12 weeks. Subjects completed the KHQ at
baseline and end of treatment. The KHQ includes 9 domains
with 21 items and a Symptom Severity scale; lower scores indi-
cate better HRQL. Analysis of covariance was used to assess
treatment-related effects on the 21 individual items of the 9 KHQ
domains, with treatment and region as factors and baseline value
as a covariate. RESULTS: By the end of the study, FESO 8 mg
signiﬁcantly improved responses to 13 items vs. PBO; in com-
parison, FESO 4 mg and TER improved responses to 9 and 8
items, respectively (all P < 0.01). There were no signiﬁcant dif-
ferences between treatment groups. Seven items did not improve
with any treatment; most of these items were part of the Personal
Relationships and General Health Perception domains. In
general, items that improved the most with treatment had higher
baseline values (ie, worse HRQL) compared with those that did
not improve. CONCLUSION: Both doses of FESO (4 and 8 mg)
signiﬁcantly improved HRQL in subjects with OAB as evidenced
by signiﬁcantly better scores for 9 and 13 items of the KHQ vs
PBO, respectively. The domains showing improvement were
those for which improvement with OAB treatment would be
expected.
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OBJECTIVE: Measuring the treatment effectiveness from the
patients’ perspectives is recommended in managing benign pro-
static hyperplasia (BPH). The purpose of this study was to vali-
date the US English Patient Perception of Study Medication
Questionnaire (PPSMQ) administered to BPH patients in a
randomized clinical trial. METHODS: Patients with moderate-
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